Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16951136 | 0.88 | GABRA1 (0.44) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL423182 | 0.87 | CYP1A2 (0.68) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL9321395 | 0.86 | GABRA1 (0.43) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL2737288 | 0.85 | LMNA (0.46) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL22989563 | 0.83 | GABRA1 (0.44) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL9967747 | 0.83 | GABRA1 (0.44) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL10591236 | 0.83 | GABRA1 (0.44) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL21893895 | 0.83 | GABRA1 (0.60) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL3794555 | 0.83 | CYP3A4 (0.47) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL16958189 | 0.82 | LMNA (0.40) | GABRA1LMNACYP1A2CYP3A4GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106892945-A | A kind of N-heterocyclic carbine-palladium complex, its preparation method and application | 温州大学 | 2017-06-27 | — | — | CN | claimed |
| CN-118146118-B | Method for increasing the yield of isocyanate and method for producing isocyanate | 万华化学集团股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-120137139-A | Bis (1-isocyanato-1-methylethyl) benzene composition and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120081762-A | Tetramethyl room xylylene group method for synthesizing dicarbamate | 湖南方锐达科技有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-113861041-B | Compound and application thereof | 北京鼎材科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118146118-A | Method for increasing the yield of isocyanate and method for producing isocyanate | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20160122323-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20150133491-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-14 | — | — | US | disclosed |
| US-8987299-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-24 | — | — | US | disclosed |
| US-20140161736-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A (IT) | 2014-06-12 | — | — | US | disclosed |
| CN-102432411-A | Nitrogen-heterocyclic-cabbeen-palladium-iminazole complex for catalyzing application of aryl chloride in amination reaction | UNIV WENZHOU | 2012-05-02 | — | — | CN | disclosed |
| US-20110230680-A1 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-09-22 | — | — | US | disclosed |
| US-7977286-B2 | Substituted N,N'-diaryl-m-phenylenediamines impart good levels of oxidation inhibition in lubricants, hydraulic fluids; lubricant is a synthetic oil derived from a Fischer-Tropsch wax via palladium/phosphine complex coupling catalyst; engine, industrial, marine, hydraulic, aviation, driveline oils | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2029706-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | ExxonMobil Research and Engineering Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007133462-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265178-A1 | Lubricating compositions containing ashless catalytic antioxidant additives | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | GABRA1 2966/4885LMNA 4438/4885CYP1A2 486/4885 |
| US-20160122323-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK9, CDK6 | GABRA1 4407/4885LMNA 1932/4885CYP1A2 1410/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | GABRA1 2966/4885LMNA 4438/4885CYP1A2 486/4885 |
| US-20070265178-A1 | Lubricating compositions containing ashless catalytic antioxidant additives | GPX4, SOD1, GPX1 | GABRA1 4834/4885LMNA 3619/4885CYP1A2 1365/4885 |
| US-20140161736-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | GABRA1 113/4885LMNA 2681/4885CYP1A2 303/4885 |
| US-20150133491-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | GABRA1 113/4885LMNA 2681/4885CYP1A2 303/4885 |
| US-20110230680-A1 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | GPX4, SOD1, GPX1 | GABRA1 4828/4885LMNA 3636/4885CYP1A2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.